Tag Archives: intrexon

April, 2017

3 April
Intrexon, Ziopharm and Merck KGaA Provide Update on the Development of their CAR-T Therapy

GERMANTOWN, Md. and BOSTON, April 03, 2017 (GLOBE NEWSWIRE) — Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ZIOPHARM Oncology (NASDAQ:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Merck KGaA, Darmstadt, Germany, a leading …
Share

25 January
Intrexon to Acquire GenVec for Gene Delivery Technology

GERMANTOWN, Md., and GAITHERSBURG, Md., Jan. 24, 2017 /PRNewswire/ — Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it has entered into a definitive agreement to acquire GenVec, Inc. (NASDAQ: GNVC), a …
Share

30 March
Merck Serono and Intrexon Strike CAR-T Therapy Collaboration

Merck Serono is partnering with Intrexon Corporation to develop Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. The companies announced today that they have entered an exclusive strategic collaboration and license agreement for CAR-T cancer drugs, advancing Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s …
Share

16 February
Intrexon to Acquire Synthetic Biology Startup ActoGeniX for $60 Million

Intrexon Corporation recently announced that it will acquire ActoGeniX for $60 million. Intrexon said that it has entered into a definitive agreement to acquire the European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics. Under the agreement, Intrexon will trade $30 million in cash and another $30 …
Share

26 January
Intrexon to Buy Remaining Stake in Exemplar Genetics

Today, Intrexon Corporation announced that it has launched a tender offer to acquire the remaining stake in Exemplar Genetics, which it did not acquire through its purchase of Trans Ova Genetics. Exemplar is focused on enabling the study of life-threatening human diseases. By using its proprietary technologies in animal genetics, …
Share
14 January
Intrexon and Ziopharm Oncology Enter CAR-T License Deal with MD Anderson

Intrexon Corporation and its oncology partner Ziopharm Oncology have entered an immunotherapy deal with MD Anderson Cancer Center. The companies announced that they have entered into a broad exclusive licensing agreement with the cancer center, including an exclusive sublicensing agreement through MD Anderson for intellectually property developed at the University …
Share